Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Myriad Genetics, Inc. specializes in molecular diagnostics and genetic testing, primarily focusing on oncology and women's health. The company differentiates itself through its proprietary tests, such as the BRACAnalysis for hereditary breast and ovarian cancer, which are critical in personalized medicine. Its strong gross margin of 69.9% reflects its pricing power in a niche market.
Myriad Genetics generates revenue through a portfolio of genetic tests that aid in disease risk assessment and treatment decisions. The company benefits from high margins due to the specialized nature of its offerings and the increasing demand for personalized medicine. Its competitive advantages include a robust intellectual property portfolio and established relationships with healthcare providers.
Regulatory approvals for new genetic tests
Partnerships with healthcare providers and payers
Trends in personalized medicine adoption
Changes in reimbursement policies for genetic testing
Regulatory changes affecting genetic testing approvals
Technological advancements that could render current tests obsolete
Emergence of new competitors in the genetic testing space
Price competition from larger diagnostic firms
Negative operating cash flow impacting liquidity
High net losses affecting investor confidence
moderate - The demand for genetic testing can be influenced by overall healthcare spending, which is correlated with GDP growth.
Interest rates can affect Myriad's cost of capital and funding for R&D, but the direct impact on demand for genetic testing is limited.
minimal - The company has a manageable debt-to-equity ratio of 0.63, indicating limited reliance on external financing.
growth - Investors are likely attracted to Myriad for its potential in the expanding field of personalized medicine and genetic testing.
high - The stock has shown volatility, reflecting market sentiment and regulatory developments.